Acute effects of an oral supplement of (−)-epicatechin on postprandial fat and carbohydrate metabolism in normal and overweight subjects
Postprandial hyperglycemia, in particular when accompanied by excessive hypertriglyceridemia, is associated with increased cardiovascular risk, mainly in overweight or obese subjects, as it favors oxidative stress, systemic inflammation and endothelial dysfunction. Thus, treatments that favorably mo...
Saved in:
Published in | Food & function Vol. 5; no. 3; pp. 521 - 527 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
01.03.2014
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Postprandial hyperglycemia, in particular when accompanied by excessive hypertriglyceridemia, is associated with increased cardiovascular risk, mainly in overweight or obese subjects, as it favors oxidative stress, systemic inflammation and endothelial dysfunction. Thus, treatments that favorably modulate metabolism by reducing steep increases in postprandial serum glucose and triglycerides, are of considerable interest. Evidence suggests that (−)-epicatechin (EPI) is responsible for reductions in cardiometabolic risk associated with chocolate consumption; these effects may be associated with favorable effects of EPI on postprandial metabolism. The aims of this study were to assess the effects of EPI on postprandial metabolism in normal-weight and overweight/obese subjects. Twenty adult volunteers (normal and overweight) underwent oral metabolic tolerance tests in the absence and presence of oral EPI (1 mg kg
−1
). Metabolic responses were examined using indirect calorimetry and determining blood glucose and triglycerides at 0, 2 and 4 hours after metabolic load ingestion. Results show that EPI increased postprandial lipid catabolism, as evidenced by a significant decrease in the respiratory quotient, which implies an increase in fat oxidation. The effect was associated with significantly lower postprandial plasma glucose and triglycerides concentrations. The effects were more prominent in overweight subjects. In conclusion, EPI modulates postprandial metabolism by enhancing lipid oxidation accompanied by reductions in glycemia and triglyceridemia.
(−)-Epicatechin modulates postprandial metabolism by enhancing fat oxidation. |
---|---|
AbstractList | Postprandial hyperglycemia, in particular when accompanied by excessive hypertriglyceridemia, is associated with increased cardiovascular risk, mainly in overweight or obese subjects, as it favors oxidative stress, systemic inflammation and endothelial dysfunction. Thus, treatments that favorably modulate metabolism by reducing steep increases in postprandial serum glucose and triglycerides, are of considerable interest. Evidence suggests that (−)-epicatechin (EPI) is responsible for reductions in cardiometabolic risk associated with chocolate consumption these effects may be associated with favorable effects of EPI on postprandial metabolism.
The aims of this study were to assess the effects of EPI on postprandial metabolism in normal-weight and overweight/obese subjects.
Twenty adult volunteers (normal and overweight) underwent oral metabolic tolerance tests in the absence and presence of oral EPI (1 mg/kg). Metabolic responses were examined using indirect calorimetry and determining blood glucose and triglycerides at 0, 2 and 4 hours after metabolic load ingestion.
Results show that EPI increased postprandial lipid catabolism, as evidenced by a significant decrease in the respiratory quotient, which implies an increase in fat oxidation. The effect was associated with significantly lower postprandial plasma glucose and triglycerides concentrations. The effects were more prominent in overweight subjects.
In conclusion, EPI modulates postprandial metabolism by enhancing lipid oxidation accompanied by reductions in glycemia and triglyceridemia. Postprandial hyperglycemia, in particular when accompanied by excessive hypertriglyceridemia, is associated with increased cardiovascular risk, mainly in overweight or obese subjects, as it favors oxidative stress, systemic inflammation and endothelial dysfunction. Thus, treatments that favorably modulate metabolism by reducing steep increases in postprandial serum glucose and triglycerides, are of considerable interest. Evidence suggests that (-)-epicatechin (EPI) is responsible for reductions in cardiometabolic risk associated with chocolate consumption; these effects may be associated with favorable effects of EPI on postprandial metabolism. The aims of this study were to assess the effects of EPI on postprandial metabolism in normal-weight and overweight/obese subjects. Twenty adult volunteers (normal and overweight) underwent oral metabolic tolerance tests in the absence and presence of oral EPI (1 mg kg(-1)). Metabolic responses were examined using indirect calorimetry and determining blood glucose and triglycerides at 0, 2 and 4 hours after metabolic load ingestion. Results show that EPI increased postprandial lipid catabolism, as evidenced by a significant decrease in the respiratory quotient, which implies an increase in fat oxidation. The effect was associated with significantly lower postprandial plasma glucose and triglycerides concentrations. The effects were more prominent in overweight subjects. In conclusion, EPI modulates postprandial metabolism by enhancing lipid oxidation accompanied by reductions in glycemia and triglyceridemia.Postprandial hyperglycemia, in particular when accompanied by excessive hypertriglyceridemia, is associated with increased cardiovascular risk, mainly in overweight or obese subjects, as it favors oxidative stress, systemic inflammation and endothelial dysfunction. Thus, treatments that favorably modulate metabolism by reducing steep increases in postprandial serum glucose and triglycerides, are of considerable interest. Evidence suggests that (-)-epicatechin (EPI) is responsible for reductions in cardiometabolic risk associated with chocolate consumption; these effects may be associated with favorable effects of EPI on postprandial metabolism. The aims of this study were to assess the effects of EPI on postprandial metabolism in normal-weight and overweight/obese subjects. Twenty adult volunteers (normal and overweight) underwent oral metabolic tolerance tests in the absence and presence of oral EPI (1 mg kg(-1)). Metabolic responses were examined using indirect calorimetry and determining blood glucose and triglycerides at 0, 2 and 4 hours after metabolic load ingestion. Results show that EPI increased postprandial lipid catabolism, as evidenced by a significant decrease in the respiratory quotient, which implies an increase in fat oxidation. The effect was associated with significantly lower postprandial plasma glucose and triglycerides concentrations. The effects were more prominent in overweight subjects. In conclusion, EPI modulates postprandial metabolism by enhancing lipid oxidation accompanied by reductions in glycemia and triglyceridemia. Postprandial hyperglycemia, in particular when accompanied by excessive hypertriglyceridemia, is associated with increased cardiovascular risk, mainly in overweight or obese subjects, as it favors oxidative stress, systemic inflammation and endothelial dysfunction. Thus, treatments that favorably modulate metabolism by reducing steep increases in postprandial serum glucose and triglycerides, are of considerable interest. Evidence suggests that (−)-epicatechin (EPI) is responsible for reductions in cardiometabolic risk associated with chocolate consumption; these effects may be associated with favorable effects of EPI on postprandial metabolism. The aims of this study were to assess the effects of EPI on postprandial metabolism in normal-weight and overweight/obese subjects. Twenty adult volunteers (normal and overweight) underwent oral metabolic tolerance tests in the absence and presence of oral EPI (1 mg kg −1 ). Metabolic responses were examined using indirect calorimetry and determining blood glucose and triglycerides at 0, 2 and 4 hours after metabolic load ingestion. Results show that EPI increased postprandial lipid catabolism, as evidenced by a significant decrease in the respiratory quotient, which implies an increase in fat oxidation. The effect was associated with significantly lower postprandial plasma glucose and triglycerides concentrations. The effects were more prominent in overweight subjects. In conclusion, EPI modulates postprandial metabolism by enhancing lipid oxidation accompanied by reductions in glycemia and triglyceridemia. (−)-Epicatechin modulates postprandial metabolism by enhancing fat oxidation. Postprandial hyperglycemia, in particular when accompanied by excessive hypertriglyceridemia, is associated with increased cardiovascular risk, mainly in overweight or obese subjects, as it favors oxidative stress, systemic inflammation and endothelial dysfunction. Thus, treatments that favorably modulate metabolism by reducing steep increases in postprandial serum glucose and triglycerides, are of considerable interest. Evidence suggests that (-)-epicatechin (EPI) is responsible for reductions in cardiometabolic risk associated with chocolate consumption; these effects may be associated with favorable effects of EPI on postprandial metabolism. The aims of this study were to assess the effects of EPI on postprandial metabolism in normal-weight and overweight/obese subjects. Twenty adult volunteers (normal and overweight) underwent oral metabolic tolerance tests in the absence and presence of oral EPI (1 mg kg(-1)). Metabolic responses were examined using indirect calorimetry and determining blood glucose and triglycerides at 0, 2 and 4 hours after metabolic load ingestion. Results show that EPI increased postprandial lipid catabolism, as evidenced by a significant decrease in the respiratory quotient, which implies an increase in fat oxidation. The effect was associated with significantly lower postprandial plasma glucose and triglycerides concentrations. The effects were more prominent in overweight subjects. In conclusion, EPI modulates postprandial metabolism by enhancing lipid oxidation accompanied by reductions in glycemia and triglyceridemia. Postprandial hyperglycemia, in particular when accompanied by excessive hypertriglyceridemia, is associated with increased cardiovascular risk, mainly in overweight or obese subjects, as it favors oxidative stress, systemic inflammation and endothelial dysfunction. Thus, treatments that favorably modulate metabolism by reducing steep increases in postprandial serum glucose and triglycerides, are of considerable interest. Evidence suggests that (−)-epicatechin (EPI) is responsible for reductions in cardiometabolic risk associated with chocolate consumption; these effects may be associated with favorable effects of EPI on postprandial metabolism. The aims of this study were to assess the effects of EPI on postprandial metabolism in normal-weight and overweight/obese subjects. Twenty adult volunteers (normal and overweight) underwent oral metabolic tolerance tests in the absence and presence of oral EPI (1 mg kg⁻¹). Metabolic responses were examined using indirect calorimetry and determining blood glucose and triglycerides at 0, 2 and 4 hours after metabolic load ingestion. Results show that EPI increased postprandial lipid catabolism, as evidenced by a significant decrease in the respiratory quotient, which implies an increase in fat oxidation. The effect was associated with significantly lower postprandial plasma glucose and triglycerides concentrations. The effects were more prominent in overweight subjects. In conclusion, EPI modulates postprandial metabolism by enhancing lipid oxidation accompanied by reductions in glycemia and triglyceridemia. |
Author | Rubio-Gayosso, Ivan Ortiz-Vilchis, Pilar Meaney, Eduardo Villarreal, Francisco Gutiérrez-Salmeán, Gabriela Ramírez-Sánchez, Israel Vacaseydel, Claudia M Ceballos, Guillermo |
AuthorAffiliation | University of California San Diego Instituto Politécnico Nacional Department of Medicine Escuela Superior de Medicina Laboratorio de Investigación Integral Cardiometabólica |
AuthorAffiliation_xml | – name: Laboratorio de Investigación Integral Cardiometabólica – name: University of California San Diego – name: Escuela Superior de Medicina – name: Instituto Politécnico Nacional – name: Department of Medicine – name: 2 University of California San Diego, Department of Medicine. La Jolla, CA, USA – name: 1 Laboratorio de Investigación Integral Cardiometabólica. Escuela Superior de Medicina, Instituto Politécnico Nacional. México City, México |
Author_xml | – sequence: 1 givenname: Gabriela surname: Gutiérrez-Salmeán fullname: Gutiérrez-Salmeán, Gabriela – sequence: 2 givenname: Pilar surname: Ortiz-Vilchis fullname: Ortiz-Vilchis, Pilar – sequence: 3 givenname: Claudia M surname: Vacaseydel fullname: Vacaseydel, Claudia M – sequence: 4 givenname: Ivan surname: Rubio-Gayosso fullname: Rubio-Gayosso, Ivan – sequence: 5 givenname: Eduardo surname: Meaney fullname: Meaney, Eduardo – sequence: 6 givenname: Francisco surname: Villarreal fullname: Villarreal, Francisco – sequence: 7 givenname: Israel surname: Ramírez-Sánchez fullname: Ramírez-Sánchez, Israel – sequence: 8 givenname: Guillermo surname: Ceballos fullname: Ceballos, Guillermo |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24458104$$D View this record in MEDLINE/PubMed |
BookMark | eNqFks1OFjEUhhuDEUQ27jXjDklGO52Z_mxICBExIXGjibum7ZzyFWemY9vBcAeGJZfoldDJB59ijHbTpud53_PTPkVbox8BoecVflPhWrw1tfUUNxX9-gjtENyQkrb4y9b9uRF0G-3FeIHzqoXggj9B26RpWl7hZgddH5k5QQHWgkmx8LZQY-GD6os4T1MPA4xpud3_-ePmdQmTMyqBWbkMjcXkY5qCGjuXeatS1naFUUH71VUXMlgMkJT2vYtDkSWjD0MmF8pfQvgO7nyVciJ9sSR_hh5b1UfYu9t30eeTd5-OT8uzj-8_HB-dlabhIpWMsRpa2mqtBes4B00tq1jbGEENsRQ0pwAUKsWt7YBUBBhlWauM4sKyehcdrn2nWQ_Qmdxh7ldOwQ0qXEmvnHwYGd1KnvtLWYuGMUGywf6dQfDfZohJDi4a6Hs1gp-jJHWbB8zyhP-LVi0mQjBCeEZf_l7Wpp77t8rAwRowwccYwG6QCsvlL8hffyHD-A_YuKSS80tLrv-75MVaEqLZWD-Iv_pXXE6drW8BiybQoA |
CitedBy_id | crossref_primary_10_1016_j_freeradbiomed_2018_11_010 crossref_primary_10_3390_diseases4040039 crossref_primary_10_1016_j_clnu_2021_11_030 crossref_primary_10_1039_C9FO00918C crossref_primary_10_1093_nutrit_nux028 crossref_primary_10_1016_j_jnutbio_2019_108296 crossref_primary_10_1055_a_1843_9855 crossref_primary_10_1155_2016_5630985 crossref_primary_10_3945_jn_115_215772 crossref_primary_10_3390_nu11020417 crossref_primary_10_1093_ajcn_nqy066 crossref_primary_10_3389_fphys_2015_00296 crossref_primary_10_1186_s12944_021_01487_9 crossref_primary_10_2478_s11756_019_00343_7 crossref_primary_10_1093_nutrit_nux070 crossref_primary_10_3390_antiox10030467 crossref_primary_10_3390_nu14061316 crossref_primary_10_1016_j_ijcard_2016_08_158 crossref_primary_10_1186_s41110_020_00118_0 crossref_primary_10_1016_j_freeradbiomed_2016_01_016 crossref_primary_10_1016_j_abb_2020_108505 crossref_primary_10_1051_e3sconf_202123302032 crossref_primary_10_3389_fnut_2018_00132 crossref_primary_10_1016_j_jff_2023_105751 crossref_primary_10_1089_jmf_2019_0201 crossref_primary_10_3390_cells10061346 crossref_primary_10_1039_C7FO01028A crossref_primary_10_3390_nu13020571 crossref_primary_10_1016_j_heliyon_2019_e01512 crossref_primary_10_1007_s40496_024_00390_3 crossref_primary_10_31883_pjfns_131061 crossref_primary_10_3390_ijms17111877 crossref_primary_10_3390_nu15245136 crossref_primary_10_1039_C5FO00750J crossref_primary_10_1016_j_jnutbio_2015_12_008 crossref_primary_10_3390_jcm13010195 crossref_primary_10_3390_sports8020022 crossref_primary_10_3390_nu12071902 crossref_primary_10_1007_s00424_021_02640_0 |
Cites_doi | 10.1080/07315724.2007.10719627 10.4158/EP.13.S1.1 10.1021/jf0603681 10.4093/dmj.2011.35.4.404 10.1016/j.metabol.2008.06.014 10.1248/jhs.51.248 10.3109/17477166.2010.543684 10.1089/ars.2010.3697 10.3945/ajcn.112.040469 10.1016/j.brainresbull.2011.07.001 10.3390/nu2070737 10.2337/diabetes.51.2007.S258 10.1016/j.clinthera.2012.04.012 10.1111/j.1463-1326.2004.00407.x 10.1155/2011/676208 10.2337/dc09-2191 10.1016/j.nutres.2009.10.003 10.1038/ejcn.2010.47 10.4065/mcp.2010.0434 10.1517/14656566.7.8.1055 10.1093/gerona/glr235 10.1016/j.metabol.2011.06.008 10.1046/j.1365-201X.2003.01164.x 10.1093/ajcn/87.3.778 10.3109/09637486.2011.636346 10.1113/jphysiol.2011.209924 10.4162/nrp.2011.5.1.28 10.1038/ijo.2010.5 10.4158/EP.14.1.112 10.1017/S0007114511005083 |
ContentType | Journal Article |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7S9 L.6 5PM |
DOI | 10.1039/c3fo60416k |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic AGRICOLA AGRICOLA - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE AGRICOLA |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Diet & Clinical Nutrition |
EISSN | 2042-650X |
EndPage | 527 |
ExternalDocumentID | PMC3947792 24458104 10_1039_c3fo60416k c3fo60416k |
Genre | Clinical Trial Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NIMHD NIH HHS grantid: P60 MD000220 – fundername: NCCIH NIH HHS grantid: R21 AT004277 – fundername: NIMHD NIH HHS grantid: P60MD001 – fundername: NCCIH NIH HHS grantid: AT4277 – fundername: NIDDK NIH HHS grantid: DK98717 – fundername: NIDDK NIH HHS grantid: R24 DK092154 – fundername: NHLBI NIH HHS grantid: HL43617 – fundername: NHLBI NIH HHS grantid: R01 HL043617 |
GroupedDBID | --- 0-7 0R~ 4.4 53G 705 7~J AAEMU AAHBH AAIWI AAJAE AANOJ AARTK AAWGC AAXHV AAYXX ABASK ABDVN ABEMK ABIQK ABJNI ABPDG ABRYZ ABXOH ACGFS ACLDK ACPRK ACRPL ADMRA ADNMO ADSRN AEFDR AENEX AENGV AESAV AETIL AFLYV AFOGI AFRAH AFRZK AFVBQ AGEGJ AGQPQ AGRSR AHGCF AHGXI AKBGW AKMSF ALMA_UNASSIGNED_HOLDINGS ALSGL ANBJS ANLMG ANUXI APEMP ASKNT ASPBG AUDPV AVWKF AZFZN BLAPV BSQNT C6K CAG CITATION COF EBS ECGLT EE0 EF- EJD FEDTE GGIMP H13 HVGLF HZ~ H~N J3G J3H J3I L-8 O-G O9- P2P RAOCF RCNCU RNS RPMJG RSCEA RVUXY SKF SKH SKJ SKM SKR SKZ SLC SLF CGR CUY CVF ECM EIF NPM 7X8 7S9 L.6 5PM |
ID | FETCH-LOGICAL-c489t-7773e565bbb97d88eb6f71754c96c2f6eb86ee6e1a8ffde212e767c48aca89f73 |
ISSN | 2042-6496 2042-650X |
IngestDate | Thu Aug 21 13:43:22 EDT 2025 Fri Jul 11 12:31:00 EDT 2025 Fri Jul 11 11:55:00 EDT 2025 Mon Jul 21 05:55:04 EDT 2025 Tue Jul 01 02:37:31 EDT 2025 Thu Apr 24 23:08:31 EDT 2025 Thu May 19 04:20:30 EDT 2016 Thu May 30 17:43:46 EDT 2019 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c489t-7773e565bbb97d88eb6f71754c96c2f6eb86ee6e1a8ffde212e767c48aca89f73 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 Drs. Ramírez-Sánchez and Ceballos co-senior this work |
PMID | 24458104 |
PQID | 1502997228 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | crossref_citationtrail_10_1039_c3fo60416k proquest_miscellaneous_1502997228 crossref_primary_10_1039_c3fo60416k rsc_primary_c3fo60416k proquest_miscellaneous_2352447581 pubmedcentral_primary_oai_pubmedcentral_nih_gov_3947792 pubmed_primary_24458104 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2014-03-01 |
PublicationDateYYYYMMDD | 2014-03-01 |
PublicationDate_xml | – month: 03 year: 2014 text: 2014-03-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Food & function |
PublicationTitleAlternate | Food Funct |
PublicationYear | 2014 |
References | O'Keefe (c3fo60416k-(cit3)/*[position()=1]) 2011; 86 Kurihara (c3fo60416k-(cit11)/*[position()=1]) 2006; 54 Ruderman (c3fo60416k-(cit28)/*[position()=1]) 2003; 178 Katz (c3fo60416k-(cit8)/*[position()=1]) 2011; 15 Chen (c3fo60416k-(cit14b)/*[position()=1]) 2009; 29 Briones (c3fo60416k-(cit5)/*[position()=1]) 2006; 7 Linderborg (c3fo60416k-(cit22a)/*[position()=1]) 2012; 63 Simon (c3fo60416k-(cit16)/*[position()=1]) 2002; 51 Ramos-Roman (c3fo60416k-(cit19)/*[position()=1]) 2012; 61 Mohamed (c3fo60416k-(cit9)/*[position()=1]) 2011; 86 Derosa (c3fo60416k-(cit7)/*[position()=1]) 2012; 34 Crandall (c3fo60416k-(cit24)/*[position()=1]) 2012; 67 Jang (c3fo60416k-(cit21a)/*[position()=1]) 2008; 57 Crisp (c3fo60416k-(cit18)/*[position()=1]) 2011; 6 James (c3fo60416k-(cit4)/*[position()=1]) 2005; 7 Nogueira (c3fo60416k-(cit14a)/*[position()=1]) 2011; 589 Lee (c3fo60416k-(cit15)/*[position()=1]) 2011; 35 Harada (c3fo60416k-(cit26)/*[position()=1]) 2005; 51 Okorodudu (c3fo60416k-(cit13)/*[position()=1]) 2010; 34 Murase (c3fo60416k-(cit22b)/*[position()=1]) 2012; 107 Rodbard (c3fo60416k-(cit17)/*[position()=1]) 2007; 13 Boschmann (c3fo60416k-(cit23)/*[position()=1]) 2007; 26 Arnolds (c3fo60416k-(cit6)/*[position()=1]) 2010; 33 De Gottardi (c3fo60416k-(cit10)/*[position()=1]) 2012; 96 Bell (c3fo60416k-(cit2)/*[position()=1]) 2008; 14 Aoi (c3fo60416k-(cit27)/*[position()=1]) 2011; 2011 Lee (c3fo60416k-(cit25)/*[position()=1]) 2011; 5 Thielecke (c3fo60416k-(cit12)/*[position()=1]) 2010; 64 Venables (c3fo60416k-(cit20)/*[position()=1]) 2008; 87 Meydani (c3fo60416k-(cit21b)/*[position()=1]) 2010; 2 22219517 - J Gerontol A Biol Sci Med Sci. 2012 Dec;67(12):1307-12 22098442 - Int J Food Sci Nutr. 2012 Jun;63(4):483-90 16722815 - Expert Opin Pharmacother. 2006 Jun;7(8):1055-64 21270290 - Mayo Clin Proc. 2011 Feb;86(2):128-38 22254051 - Nutrients. 2010 Jul;2(7):737-51 21244226 - Int J Pediatr Obes. 2011 Jun;6(2-2):e615-21 22811444 - Am J Clin Nutr. 2012 Sep;96(3):584-90 18940397 - Metabolism. 2008 Nov;57(11):1576-83 21773023 - J Nutr Metab. 2011;2011:676208 17613449 - Endocr Pract. 2007 May-Jun;13 Suppl 1:1-68 19932867 - Nutr Res. 2009 Nov;29(11):784-93 21788351 - J Physiol. 2011 Sep 15;589(Pt 18):4615-31 17906192 - J Am Coll Nutr. 2007 Aug;26(4):389S-395S 16819905 - J Agric Food Chem. 2006 Jul 12;54(14):4977-81 21820684 - Metabolism. 2012 Feb;61(2):202-12 20357372 - Diabetes Care. 2010 Jul;33(7):1509-15 11815489 - Diabetes. 2002 Feb;51 Suppl 1:S258-61 15955124 - Diabetes Obes Metab. 2005 Jul;7(4):381-9 21487493 - Nutr Res Pract. 2011 Feb;5(1):28-33 22560622 - Clin Ther. 2012 Jun;34(6):1221-36 12864749 - Acta Physiol Scand. 2003 Aug;178(4):435-42 21977461 - Diabetes Metab J. 2011 Aug;35(4):404-10 21763406 - Brain Res Bull. 2011 Aug 10;86(1-2):22-8 18238751 - Endocr Pract. 2008 Jan-Feb;14(1):112-24 22017960 - Br J Nutr. 2012 Jun;107(12):1757-65 20372175 - Eur J Clin Nutr. 2010 Jul;64(7):704-13 20125098 - Int J Obes (Lond). 2010 May;34(5):791-9 18326618 - Am J Clin Nutr. 2008 Mar;87(3):778-84 21470061 - Antioxid Redox Signal. 2011 Nov 15;15(10):2779-811 |
References_xml | – issn: 2011 publication-title: Nutritional sciences: from fundamentals to food doi: McGuire Beerman – volume: 26 start-page: 389S issue: 4 year: 2007 ident: c3fo60416k-(cit23)/*[position()=1] publication-title: J. Am. Coll. Nutr. doi: 10.1080/07315724.2007.10719627 – volume: 13 start-page: 1 issue: suppl. 1 year: 2007 ident: c3fo60416k-(cit17)/*[position()=1] publication-title: Endocr Pract doi: 10.4158/EP.13.S1.1 – volume: 54 start-page: 4977 issue: 14 year: 2006 ident: c3fo60416k-(cit11)/*[position()=1] publication-title: J. Agric. Food Chem. doi: 10.1021/jf0603681 – volume: 35 start-page: 404 year: 2011 ident: c3fo60416k-(cit15)/*[position()=1] publication-title: J. Diabetes Metab. doi: 10.4093/dmj.2011.35.4.404 – volume: 57 start-page: 1576 issue: 11 year: 2008 ident: c3fo60416k-(cit21a)/*[position()=1] publication-title: Metab., Clin. Exp. doi: 10.1016/j.metabol.2008.06.014 – volume: 51 start-page: 248 year: 2005 ident: c3fo60416k-(cit26)/*[position()=1] publication-title: J. Health Sci. doi: 10.1248/jhs.51.248 – volume: 6 start-page: e615 issue: 2–2 year: 2011 ident: c3fo60416k-(cit18)/*[position()=1] publication-title: Int. J. Pediatr. Obes. doi: 10.3109/17477166.2010.543684 – volume: 15 start-page: 2779 year: 2011 ident: c3fo60416k-(cit8)/*[position()=1] publication-title: Antioxid. Redox Signaling doi: 10.1089/ars.2010.3697 – volume: 96 start-page: 584 issue: 3 year: 2012 ident: c3fo60416k-(cit10)/*[position()=1] publication-title: Am. J. Clin. Nutr. doi: 10.3945/ajcn.112.040469 – volume: 86 start-page: 22 issue: 1–2 year: 2011 ident: c3fo60416k-(cit9)/*[position()=1] publication-title: Brain Res. Bull. doi: 10.1016/j.brainresbull.2011.07.001 – volume: 2 start-page: 737 issue: 7 year: 2010 ident: c3fo60416k-(cit21b)/*[position()=1] publication-title: Nutrients doi: 10.3390/nu2070737 – volume: 51 start-page: S258 year: 2002 ident: c3fo60416k-(cit16)/*[position()=1] publication-title: Diabetes doi: 10.2337/diabetes.51.2007.S258 – volume: 34 start-page: 1221 issue: 6 year: 2012 ident: c3fo60416k-(cit7)/*[position()=1] publication-title: Clin. Ther. doi: 10.1016/j.clinthera.2012.04.012 – volume: 7 start-page: 381 issue: 4 year: 2005 ident: c3fo60416k-(cit4)/*[position()=1] publication-title: Diabetes, Obes. Metab. doi: 10.1111/j.1463-1326.2004.00407.x – volume: 2011 start-page: 676208 year: 2011 ident: c3fo60416k-(cit27)/*[position()=1] publication-title: J. Nutr. Metab. doi: 10.1155/2011/676208 – volume: 33 start-page: 1509 issue: 7 year: 2010 ident: c3fo60416k-(cit6)/*[position()=1] publication-title: Diabetes Care doi: 10.2337/dc09-2191 – volume: 29 start-page: 784 issue: 11 year: 2009 ident: c3fo60416k-(cit14b)/*[position()=1] publication-title: Nutr. Res. doi: 10.1016/j.nutres.2009.10.003 – volume: 64 start-page: 704 issue: 7 year: 2010 ident: c3fo60416k-(cit12)/*[position()=1] publication-title: Eur. J. Clin. Nutr. doi: 10.1038/ejcn.2010.47 – volume: 86 start-page: 128 issue: 2 year: 2011 ident: c3fo60416k-(cit3)/*[position()=1] publication-title: Mayo Clin. Proc. doi: 10.4065/mcp.2010.0434 – volume: 7 start-page: 1055 issue: 8 year: 2006 ident: c3fo60416k-(cit5)/*[position()=1] publication-title: Expert Opin. Pharmacother. doi: 10.1517/14656566.7.8.1055 – volume: 67 start-page: 1307 year: 2012 ident: c3fo60416k-(cit24)/*[position()=1] publication-title: J. Gerontol., Ser. A doi: 10.1093/gerona/glr235 – volume: 61 start-page: 202 issue: 2 year: 2012 ident: c3fo60416k-(cit19)/*[position()=1] publication-title: Metab., Clin. Exp. doi: 10.1016/j.metabol.2011.06.008 – volume: 178 start-page: 435 issue: 4 year: 2003 ident: c3fo60416k-(cit28)/*[position()=1] publication-title: Acta Physiol. Scand. doi: 10.1046/j.1365-201X.2003.01164.x – volume: 87 start-page: 778 issue: 3 year: 2008 ident: c3fo60416k-(cit20)/*[position()=1] publication-title: Am. J. Clin. Nutr. doi: 10.1093/ajcn/87.3.778 – volume: 63 start-page: 483 issue: 4 year: 2012 ident: c3fo60416k-(cit22a)/*[position()=1] publication-title: Int. J. Food Sci. Nutr. doi: 10.3109/09637486.2011.636346 – volume: 589 start-page: 4615 issue: 18 year: 2011 ident: c3fo60416k-(cit14a)/*[position()=1] publication-title: J. Physiol. doi: 10.1113/jphysiol.2011.209924 – volume: 5 start-page: 28 issue: 1 year: 2011 ident: c3fo60416k-(cit25)/*[position()=1] publication-title: Nutr. Res. Pract. doi: 10.4162/nrp.2011.5.1.28 – volume: 34 start-page: 791 issue: 5 year: 2010 ident: c3fo60416k-(cit13)/*[position()=1] publication-title: Int. J. Obes. doi: 10.1038/ijo.2010.5 – volume: 14 start-page: 112 issue: 1 year: 2008 ident: c3fo60416k-(cit2)/*[position()=1] publication-title: Endocr Pract doi: 10.4158/EP.14.1.112 – volume: 107 start-page: 1757 issue: 12 year: 2012 ident: c3fo60416k-(cit22b)/*[position()=1] publication-title: Br. J. Nutr. doi: 10.1017/S0007114511005083 – reference: 22098442 - Int J Food Sci Nutr. 2012 Jun;63(4):483-90 – reference: 21270290 - Mayo Clin Proc. 2011 Feb;86(2):128-38 – reference: 11815489 - Diabetes. 2002 Feb;51 Suppl 1:S258-61 – reference: 21470061 - Antioxid Redox Signal. 2011 Nov 15;15(10):2779-811 – reference: 22219517 - J Gerontol A Biol Sci Med Sci. 2012 Dec;67(12):1307-12 – reference: 18940397 - Metabolism. 2008 Nov;57(11):1576-83 – reference: 18326618 - Am J Clin Nutr. 2008 Mar;87(3):778-84 – reference: 22254051 - Nutrients. 2010 Jul;2(7):737-51 – reference: 19932867 - Nutr Res. 2009 Nov;29(11):784-93 – reference: 21788351 - J Physiol. 2011 Sep 15;589(Pt 18):4615-31 – reference: 21977461 - Diabetes Metab J. 2011 Aug;35(4):404-10 – reference: 17906192 - J Am Coll Nutr. 2007 Aug;26(4):389S-395S – reference: 20372175 - Eur J Clin Nutr. 2010 Jul;64(7):704-13 – reference: 20357372 - Diabetes Care. 2010 Jul;33(7):1509-15 – reference: 17613449 - Endocr Pract. 2007 May-Jun;13 Suppl 1:1-68 – reference: 21773023 - J Nutr Metab. 2011;2011:676208 – reference: 21244226 - Int J Pediatr Obes. 2011 Jun;6(2-2):e615-21 – reference: 22017960 - Br J Nutr. 2012 Jun;107(12):1757-65 – reference: 20125098 - Int J Obes (Lond). 2010 May;34(5):791-9 – reference: 18238751 - Endocr Pract. 2008 Jan-Feb;14(1):112-24 – reference: 12864749 - Acta Physiol Scand. 2003 Aug;178(4):435-42 – reference: 21763406 - Brain Res Bull. 2011 Aug 10;86(1-2):22-8 – reference: 16819905 - J Agric Food Chem. 2006 Jul 12;54(14):4977-81 – reference: 16722815 - Expert Opin Pharmacother. 2006 Jun;7(8):1055-64 – reference: 21487493 - Nutr Res Pract. 2011 Feb;5(1):28-33 – reference: 22560622 - Clin Ther. 2012 Jun;34(6):1221-36 – reference: 22811444 - Am J Clin Nutr. 2012 Sep;96(3):584-90 – reference: 21820684 - Metabolism. 2012 Feb;61(2):202-12 – reference: 15955124 - Diabetes Obes Metab. 2005 Jul;7(4):381-9 |
SSID | ssj0000399898 |
Score | 2.202279 |
Snippet | Postprandial hyperglycemia, in particular when accompanied by excessive hypertriglyceridemia, is associated with increased cardiovascular risk, mainly in... |
SourceID | pubmedcentral proquest pubmed crossref rsc |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 521 |
SubjectTerms | acute effects Adult adults biochemical pathways blood glucose Blood Glucose - metabolism calorimetry carbohydrate metabolism Carbohydrate Metabolism - drug effects Catechin - administration & dosage chocolate Fats - metabolism Female Humans hyperglycemia Hyperglycemia - drug therapy Hyperglycemia - metabolism hypertriglyceridemia inflammation lipid metabolism lipid peroxidation Male overweight Overweight - drug therapy Overweight - metabolism oxidative stress respiratory quotient risk triacylglycerols Triglycerides - blood volunteers |
Title | Acute effects of an oral supplement of (−)-epicatechin on postprandial fat and carbohydrate metabolism in normal and overweight subjects |
URI | https://www.ncbi.nlm.nih.gov/pubmed/24458104 https://www.proquest.com/docview/1502997228 https://www.proquest.com/docview/2352447581 https://pubmed.ncbi.nlm.nih.gov/PMC3947792 |
Volume | 5 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLa67oUXNC6DjIuMQIg9eDT35LEM1gFiINhG3yI7cbSKkERpitT-An4Nv5FznGtpJwEvUZsc10nPF_t89rkQ8swJYwyx9pmw-YhZYNAyTwiXRY4whCvkyIww3vnDmXN6Yb2b2tPB4FfPa2lRiqNwtTWu5H-0CudArxgl-w-abX8UTsBn0C8cQcNw_Csdj0Pc5e-5ZGCdCYy4n2OtTtns84MRyYDxM5mrgDf0nsQ9gjybl3mBYS0YxMgrV_OQFyK7WkaYQQLLSwNGEqyjAU1SNG-rzAKZcqdGXg9dCVzKmfet3BNMlYyYwlmzv9M_gT-j2povCrliX7B4i_quq8FvwgUw96SdKT7CI6_Y5SwJ66rJn2YJb72JL3kIU_AyqvwMjhO-gCfpVnc_L8QsYxO-BDNArQe__VG_CfUih251Xl5HUg2GBoYRgTU57Y_cdg-gZm8Utqug643ZYWRictXQjDNnBIbot74QaDb_rnACBo_t1UWR_8jF3VzaIbsG0BJjSHbH719NvraretADFuRs8uCa_suuN8w7XbdfN4I2mM2mg-5O0dSjUXbP-R65WRMWOq7Qd4sMZHqbaK9nsqTPaZ1VNqFnTVGHO-SnQiWtUUmzmPKUIipph0o8-4Id9hFJs5T2EUkBkdAyon1E0g6RFJpUiFRSHSJpg8i75OLkzfnxKavrfbDQ8vwSiJ5rSiAYQgjfjTxPCid2wby1Qt8JjdiRwnOkdKTOvTiOJBhd0nVcaAtw8_zYNffJMM1SeZ9QKwbaA1SaSywQIbiwvVAfRX7keDowEFMjh40CgrBOho81WZJAOWWYftDpTSNPW9m8SgGzVepJo8cARmjcduOpzBbzACiXgeHphne9jAE8CFNverpG7lW6b_tqQKMRdw0VrQBmiF-_ks6uVKZ407dc1zc0sg_4aeX7N32w_UKQR_HBtXfygNzoXtKHZFgWC_kIbPNSPK5fiN-no-tp |
linkProvider | Royal Society of Chemistry |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Acute+effects+of+an+oral+supplement+of+%28-%29-epicatechin+on+postprandial+fat+and+carbohydrate+metabolism+in+normal+and+overweight+subjects&rft.jtitle=Food+%26+function&rft.au=Guti%C3%A9rrez-Salme%C3%A1n%2C+Gabriela&rft.au=Ortiz-Vilchis%2C+Pilar&rft.au=Vacaseydel%2C+Claudia+M&rft.au=Rubio-Gayosso%2C+Ivan&rft.date=2014-03-01&rft.eissn=2042-650X&rft.volume=5&rft.issue=3&rft.spage=521&rft_id=info:doi/10.1039%2Fc3fo60416k&rft_id=info%3Apmid%2F24458104&rft.externalDocID=24458104 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2042-6496&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2042-6496&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2042-6496&client=summon |